RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.98 EUR | -4.98% |
|
+1.30% | +2.36% |
| Apr. 24 | Global markets live: Heineken, AT&T Hasbro, Visa, Boeing... |  |
| Apr. 24 | CVC Said Mulling Options for Majority Stake in Recordati | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
49.98
EUR
Average target price
51.64
EUR
Spread / Average Target
+3.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.36% | 11.58B | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- REC Stock
- News Recordati
- Recordati Confirms 2022 Financial Targets
